ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis

Cheng, Zhendong; Cai, Kefeng; Xu, Chaoxian; Zhan, Qiong; Xu, Xingbo; Xu, Dingli*; Zeng, Qingchun*南方医科大学
Frontiers in Cardiovascular Medicine2022-2-18DOI: 10.3389/fcvm.2022.783707
5被引12阅读
引用收藏
分享

摘要

Objective: To evaluate the association between serum galectin-3 and all-cause death (ACD) and cardiovascular death (CVD) in patients with chronic heart failure (CHF).Methods: The PubMed and Embase databases and Clinical Trials Registry (www.clinicaltrials.gov) were searched for studies with data on serum galectin-3 and ACD and CVD in CHF patients. The hazard ratios (HRs) of ACD and CVD were calculated and presented with 95% CIs. HRs were pooled using fixed effects or random effects models when appropriate. Sensitivity analysis, meta-regression and subgroup analysis were applied to find the origin of heterogeneity. Visual inspection of Begg's funnel plot and Egger's test were performed to assess the possibility publication bias.Results: Pooled data included the results from 6,440 patients from 12 studies in the meta-analysis. Higher serum galectin-3 was associated with a higher risk of ACD (HR, 1.38; 95% CI, 1.14-1.67) and CVD (HR, 1.13; 95% CI, 1.02-1.25) in CHF patients. In the subgroup analyses, higher serum galectin-3 was associated with an increased risk of ACD in all subgroups. The pooled HR of the shorter follow-up group (1.78; 95% CI, 1.50-2.11) was significantly higher than the pooled HR of the longer follow-up group (1.15; 95% CI, 1.05-1.25). Sensitivity analysis of eliminating one study in each turn indicated that Koukoui et al.'s study had the largest influence on the risk of all-cause death. All-cause death publication bias was not detected (Pr >|z| = 0.35 for Begg's test and P >|t| = 0.15 for Egger's test).Conclusions: Serum galectin-3 has prognostic value of both all-cause death and cardiovascular death in CHF. Serum galectin-3 could be useful for risk classification in patients with CHF.

学科与关键词

关键词
galectin-3chronic heart failureall cause deathcardiovascular deathmeta-analysis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Cardiovascular Medicine
发表日期
2022-02-18
卷期
第 9 卷
页码
783707
DOI
10.3389/fcvm.2022.783707
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81770386, 82070403]; Science and Technology Program of Guangdong Province [2021A0505030031]; Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR110105001]; Youth Science and Technology Innovation Talent Program of Guangdong TeZhi plan [2019TQ05Y136]

作者

  • C

    Cheng, Zhendong (第一作者)

    2 · fujian med univ · southern med univ

  • C

    Cai, Kefeng

    2 · fujian med univ

查看全部 7 位作者收起作者
  • X

    Xu, Chaoxian

    2 · fujian med univ

  • Z

    Zhan, Qiong

    southern med univ

  • X

    Xu, Xingbo

  • X

    Xu, Dingli (通讯)

    southern med univ

  • Z

    Zeng, Qingchun (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417